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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterised by neuropathological deposits
of amyloid plaques and neurofibrillary tangles comprised of β-amyloid and tau protein, respectively. In AD, tau
becomes abnormally phosphorylated and aggregates to form intracellular deposits. However, the mechanisms by
which tau exerts neurotoxicity in disease remain unclear. Recent studies have suggested that the presence of tau
at synapses may indicate a role in neuronal signalling, which could be disrupted in pathological conditions. The
non-receptor-associated tyrosine kinase fyn is located at the dendrite in neurons, where it was recently shown to
interact with tau to stabilise receptor complexes at the post-synaptic density. Fyn also co-localises with tau in a
proportion of neurons containing tau tangles in AD and fyn is also a tau kinase. Hence, tau-fyn interactions could
play a pathogenic role in AD. Here we report the identification of critical proline residues, Pro213, Pro216, and
Pro219, located within the fifth and sixth Pro-X-X-Pro motifs in the proline-rich region of tau, that are important
for its binding to fyn. These residues in tau are flanked by numerous phosphorylation sites and therefore we
investigated the relationship between fyn and the degree of tau phosphorylation in human post-mortem brain
tissue. We found no difference in the amount of fyn present in control and AD brain. Notably, however, there
was a significant correlation between fyn and phosphorylated tau at specific phospho-epitopes in control, but
not in AD brain. Our results suggest that the pathological mechanisms underlying AD, that result in increased tau
phosphorylation, may disrupt the physiological relationship between tau phosphorylation and fyn.
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Introduction
The microtubule-associated protein tau has long been
recognised as having a role in stabilising microtubules in
neurons, particularly in axons. Recent evidence however,
suggests that tau is also present in dendrites where it
may play a role in synaptic function [1–3]. In support of
this suggestion, tau has been shown to associate with
synaptic proteins, such as post-synaptic density protein
95 (PSD-95) and fyn [1, 4]. In particular, a functional
role has been shown for the interaction between tau and
fyn, whereby tau directs fyn to the post-synaptic density
to interact with N-methyl-D-aspartate (NMDA) recep-
tors [1]. Direct binding of endogenous tau and fyn was
first shown in SH-SY5Y neuroblastoma cells [5]. Subse-
quently, a detailed study in mouse brain demonstrated
that a small proportion of tau interacts with fyn in den-
drites [1]. Using a truncated form of tau lacking the
microtubule-binding domain that binds to fyn but is un-
able to associate with microtubules, it was shown that
tau sequesters fyn, thereby excluding it from dendrites
and causing fyn to be translocated into the neuronal cell
body [1]. Furthermore, expression of this truncated form
of tau destabilised the interaction between fyn, NMDA
receptors, and PSD-95 [1]. Crossing amyloid precursor
protein (APP) mutant mice with transgenic mice express-
ing truncated tau ameliorated the premature mortality
and memory deficits, and reduced the susceptibility to
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excitotoxic seizures observed in APP transgenic mice [1].
These data indicate that the mis-localisation of fyn caused
by truncated tau rescued amyloid-induced phenotypes.
Therefore, tau-fyn interactions could play a functional role
in Alzheimer’s disease (AD). We have previously demon-
strated a role for fyn in the dynamic targeting of tau to the
plasma membrane in neurons [6]. We found that the
phosphorylation status of tau affects its trafficking be-
tween the cytosol and the membrane in neurons, and that
this was dependent on the region of tau that is phosphory-
lated [6]. Thus there is mounting evidence that tau-fyn
interactions could be involved in new functionalities for
tau at dendrites and in synaptic signalling [7, 8].
We focused here on identifying the binding site(s) for
the tau-fyn interaction. It is well known that SH3 do-
mains of src family kinases, of which fyn is a member,
bind to PXXP motifs [9]. Tau has seven such motifs,
some overlapping in tandem, within the proline-rich re-
gion in the N-terminal half. Therefore it is of interest to
determine which of the motifs is critical for tau-fyn in-
teractions. Previous studies to identify the critical PXXP
motif have suggested that the sixth and seventh PXXP
motifs (P216–P219 and P233–P236, respectively) are im-
portant for tau-fyn binding [10, 11], while other studies
suggested that the seventh PXXP motif, rather than the
sixth PXXP motif, was more important for tau-fyn bind-
ing [1, 5].
In this study, we extend the findings from Lee et al.
[5] and Usardi et al. [10] to include investigation of the
remaining PXXP motifs on tau using full-length, intact
tau to avoid structural changes. Furthermore, since
phosphorylation at serine and threonine residues affects
interactions between tau and fyn [7] and the relationship
between tau and fyn has not been explored extensively
in humans, we investigated whether phosphorylation of
tau around these motifs would correlate with levels of
fyn in human post-mortem brain tissue from unaffected
individuals or patients with AD.
Materials and methods
Plasmids
A plasmid expressing the longest isoform of human
CNS tau containing two N-terminal inserts and four
microtubule-binding repeats (2N4R) has been described
previously [12]. The generation of plasmids encoding
2N4R tau containing proline-to-alanine substitutions at
residues 216 (P216A) or 233 (P233A) of tau has been
described previously [10]. Site-directed mutagenesis
(QuikChange II XL, Agilent Technologies) was used to
produce 2N4R tau constructs harbouring individual
proline-to-alanine substitutions, P176A, P182A, P200A,
P206A, P213A, and P219A. The primers used are
shown in Table 1. Wild-type (WT) and mutant tau
cDNA were subcloned into the pcDNA3.1-V5-His-
TOPO vector (Invitrogen) to generate plasmids express-
ing V5-His-tagged tau. Plasmids encoding glutathione-
S-transferase (GST), or GST fused to the N-terminus
of the src homology (SH) two or three domains of fyn
were a gift from Dr S. Anderson (University of Colorado
Anschutz Medical Campus, Aurora, CO, USA) [13].
Cell culture and transfection
Chinese hamster ovary (CHO) cells were maintained in
Ham’s F-12 (GE Healthcare) supplemented with 10 %
(v/v) foetal bovine serum (Biosera), 2 mM L-glutamine,
100 U/ml penicillin, and 100 μg/ml streptomycin, and
incubated in a 5 % CO2 atmosphere at 37 °C. Cells were
plated at a density of 200,000 per well of a 6-well plate
and plasmids were transfected 24 h after plating using
jetPEI® (Polyplus Transfection), according to the manu-
facturer’s instructions. Cells were harvested 24 h after
transfection.
Pull-downs with glutathione S-transferase fusion proteins
Frozen glycerol preparations of E.coli containing GST-
and GST-fyn-SH3-encoding plasmids were streaked
across agar plates and incubated overnight at 37 °C. A
single bacterial colony was used to inoculate 5 ml LB-
amp broth and incubated overnight at 37 °C with shak-
ing, before further inoculating 250 ml LB-amp broth and
incubating for two hours at 37 °C with shaking until an
optical density of 0.6–1.0 nm was reached. 1 mM
isopropyl-1-thio-β-D-galactopyranoside (IPTG) was added
to the cultures and incubated for a further 2 h with shak-
ing. The culture was then centrifuged at 20,000 g(av) for
15 min at 4 °C to pellet the bacteria. The pellet was resus-
pended in 12 ml TNE buffer (25 mM Tris-HCl, pH 7.5,
100 mM NaCl, 1 mM ethylenediaminetetraacetic acid
(EDTA), and complete protease inhibitor cocktail without
Table 1 Primers used for site-directed mutagenesis













Primers used for site-directed mutagenesis of tau. The codons mutated to replace
proline (P) with alanine (A) in the encoded protein are underlined
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EDTA [Roche]) and homogenised by sonication (Vibra-
Cell™, Sonics & Materials Inc.) for six 15 s bursts on
ice. Triton X-100 was added to a final concentration of
1 % (v/v), mixed, and the samples were centrifuged at
30,000 g(av) for 10 min at 4 °C. The supernatant, con-
taining GST-fusion proteins, was collected and stored
on ice. A 50 % (v/v) slurry of glutathione-4B beads (GE
Healthcare, Buckinghamshire, UK) was washed three
times in TNE buffer and added to supernatant contain-
ing GST-fusion proteins and rotated for 90 min at 4 °C,
then centrifuged at 3300 g(av) for 1 min at 4 °C to pellet
the beads. Beads coupled to GST-fusion proteins were
washed three times with TNE buffer and resuspended
as a 50 % (v/v) slurry.
CHO cells transfected with WT or mutant tau were
washed with phosphate-buffered saline, harvested into
ice-cold lysis buffer (25 mM Tris-HCl, pH 7.5, 10 % (v/v)
glycerol, 0.5 % (v/v) Triton X-100, 1 mM EDTA, 1 mM
ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraace-
tic acid, 150 mM NaCl, complete protease inhibitor cock-
tail without EDTA [Roche], and phosphatase inhibitor
cocktail 2 [Sigma]), and incubated on ice for 15 min.
Lysates were centrifuged at 6000 g(av) for 5 min to pel-
let cell debris. GST-beads (50 % slurry) were washed
twice in wash buffer (50 mM Tris-HCl, pH 7.5, 2 mM
EDTA, 0.5 % (v/v) Triton X-100, 150 mM NaCl,
complete protease inhibitor cocktail without EDTA
[Roche], and phosphatase inhibitor cocktail 2 [Sigma])
and incubated with the cell lysates. The pre-cleared cell
lysates were incubated overnight at 4 °C with washed
GST-beads or GST-fyn-SH3-beads. Beads were pelleted
at 6000 g(av) for 5 min and the supernatants were dis-
carded. Beads were washed twice with wash buffer, then
Laemmli sample buffer was added and the samples
heated at 100 °C for 5 min to elute bound protein. Pro-
teins were separated on 10 % (w/v) sodium dodecyl
sulphate (SDS)-polyacrylamide gels, transferred to
nitrocellulose membranes and western blots were
probed with antibodies to total tau, as described below.
The amount of tau bound to GST-fyn-SH3 beads was
quantified using an Odyssey scanner (Li-Cor Biosci-
ences) and standardised against the total amount of tau
in the corresponding cell lysate.
Post-mortem human brain tissue
Samples of frozen temporal cortex from post-mortem
human brain (15 AD and 11 controls) were obtained
from the London Neurodegenerative Diseases Brain
Bank at the Institute of Psychiatry, Psychology and
Neuroscience, King’s College London (details in Table 2).
Samples were collected and distributed in accordance
with local and national research ethics committee
approvals (REC reference: 08/MRE09/38+5). Alzheimer
disease-related pathology was classified using diagnostic
neuropathological criteria from the consortium to estab-
lish a registry for Alzheimer’s disease (CERAD) and
Braak staging [14, 15]. The average ages of the AD and
control cases were 87.7 ± 1.4 years and 79.2 ± 3.6 years
(mean ± s.e.m), respectively. The average post-mortem
delays for the AD and control brains were 33.5 ± 5.5 h
and 24.2 ± 4.8 h (mean ± s.e.m), respectively. Brain tissue
was thawed on ice and homogenised at 100 mg/ml in 2×
Laemmli sample buffer using a mechanical homogeniser
(Ultra Turrax® T8, Werke GmbH & Co., Germany). Ho-
mogenates were briefly sonicated (Vibra-Cell™, Sonics &
Materials Inc.) before being centrifuged at 16,000 g(av) at
Table 2 Case details for control and late-stage Alzheimer’s
disease post-mortem human temporal cortex
Sample
number




stageMean 84 ± 2,
range 55–98
years
Mean 30 ± 4,
range 6–80 h
1 F 82 43 Control
2 F 81 17 I
3 F 92 17 Control
4 M 86 6 Control
5 F 55 12 I
6 M 80 21 Control
7 F 90 50 II
8 F 87 22 Control
9 M 81 18 I
10 M 78 10 Control
11 M 59 50 Control
12 M 80 41 VI
13 F 91 29 VI
14 M 88 46 VI
15 F 92 42 VI
16 F 80 13 V
17 F 82 69 V
18 F 84 36 V/VI
19 F 90 23 V/VI
20 F 98 3.5 IV
21 M 82 80 V/VI
22 F 89 15 IV
23 F 97 12 V
24 M 89 19 V/VI
25 M 86 26 V
26 F 87 48 VI
Human post-mortem brain tissue obtained from the London Neurodegenerative
Diseases Brain Bank at the Institute of Psychiatry, Psychology and Neuroscience,
King’s College London. Gender, age at death, post-mortem delay, Braak stage,
and/or diagnosis are included for each case
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4 °C for 20 min. The supernatants were collected and
stored at −80 °C.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
and western blots
Proteins were separated on 10 % (w/v) SDS-polyacrylamide
gels and transferred to nitrocellulose membranes. After
blocking, membranes were incubated overnight at 4 °C
with primary antibodies directed against total tau
(rabbit polyclonal, 1/10,000, DAKO; mouse monoclonal
CP27, 1/10,000, gift from Peter Davies), GST (goat
polyclonal, 1/2000 GE Healthcare), phosphorylated tau
(mouse monoclonal PHF-1, 1/5000, and CP13, 1/400,
both gifts from Peter Davies; rabbit polyclonal pS214,
1/500, Abcam; rabbit polyclonal pS262, 1/500, Abcam),
dephosphorylated tau (mouse monoclonal Tau-1, 1/5000,
Millipore), fyn (rabbit polyclonal, 1/1000, HPA023887,
Sigma), β-actin (mouse monoclonal, AC15, 1/10,000,
Sigma), and neuron-specific enolase (mouse monoclonal,
BBS/NC/VI-H14, 1/10,000, DAKO). Blotted membranes
were incubated with secondary antibodies (Alexa Fluor®
680 goat anti-mouse, 1/10,000, Life Technologies or
IRDye™ 800 conjugated goat anti-rabbit, 1/10,000,
Rockland Immunochemicals Inc.) and antigens were
visualised and quantified using an Odyssey scanner (Li-Cor
Biosciences).
Colloidal Coomassie blue staining of polyacrylamide gels
For analysis of GST proteins bound to glutathione
beads, SDS-polyacrylamide gels were incubated in Proto-
Blue Safe Working Solution (National Diagnostics) and
protein bands were imaged using an Odyssey scanner
(Li-Cor Biosciences).
Statistical analyses
Data were tested for normal distribution using the
D’Agostino-Pearson normality test. Normally distrib-
uted samples were analysed for statistical significance
(p < 0.05) using Student’s t-test or ANOVA. Data that
were not normally distributed were analysed using
Mann-Whitney or Kruskal-Wallis tests. Pearson’s or
Spearman’s rank correlation was used to determine cor-
relations between proteins, as appropriate. GraphPad
Prism five was used for all statistical analyses.
Results
Interaction between the fyn-SH3 domain and tau is
modulated by PXXP motifs in tau
To determine which PXXP motif is important for bind-
ing of tau to fyn-SH3, we used a GST pull-down assay
to test fyn-SH3 binding with WT tau and eight mutant
PXXP tau constructs (P176A, P182A, P200A, P206A,
P213A, P216A, P219A, and P233A) in which individual
proline residues were substituted by alanine (Fig. 1).
GST fusion proteins (GST-only or GST-fyn-SH3) coupled
to glutathione beads were prepared and the purity of the
GST proteins bound to the beads was assessed on
Coomassie blue-stained polyacrylamide gels. Following
induction of protein expression with IPTG, GST or
GST-fyn-SH3 was readily observed in the bacterial cell
lysate (Fig. 2a). Analysis of bound proteins showed sin-
gle bands at the predicted sizes for GST (27 kDa) or
GST-fyn-SH3 (32 kDa).
Fig. 1 PXXP motifs in the proline-rich region of full-length human tau. The amino acid sequence of the longest isoform of human CNS tau is
shown, with the PXXP motifs underlined and numbered (1–7). Individual proline to alanine substitutions within the PXXP motifs are indicated
by asterisks
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CHO cells were transfected with WT or mutant PXXP
tau and cell lysates were incubated with GST or GST-
fyn-SH3 beads. Proteins bound to the beads were ana-
lysed on western blots probed with an antibody against
total tau (Fig. 2b). The amount of tau bound to fyn-SH3
beads was quantified and standardised against the total
amount of tau in each cell lysate (Fig. 2c). Western blots
of the fyn-SH3 beads showed that the amounts of
P216A and P219A tau bound to fyn-SH3 was signifi-
cantly decreased to ~65 % of SH3-bound WT tau
(Fig. 2b, c; p < 0.01). Interestingly, the amount of P213A
tau bound to fyn-SH3 was significantly increased by
Fig. 2 Identification of PXXP motifs critical for tau binding to fyn-SH3. a Coomassie blue-stained gels of supernatants from cleared bacterial lysates
following induction of protein expression (Binding S/N), show glutathione S transferase (GST) and GST-fyn-SH3 at the expected sizes of 27 and
36 kDa, respectively. Specific coupling of GST or GST-fyn-SH3 proteins is shown (Beads). Molecular weight markers (kDa) are shown on the left. b
Western blots of GST-fyn-SH3 pull-downs from CHO cells expressing wild-type (WT) or mutant P→ A tau probed with antibodies recognising tau
(upper panel) or GST (middle panel). CHO cell lysates were probed with tau antibody for standardisation (lower panel). Lanes spliced from the same
blot are indicated by a dotted line. Molecular weight markers (kDa) are shown on the left. c Quantification of the amount of tau immunoreactivity
pulled down by GST-fyn-SH3, as a proportion of WT tau, following standardisation to total tau in the corresponding lysate. Values represent
mean ± SEM, n = 6–22. One-way ANOVA with post-hoc Dunnett’s test, **p < 0.01, ***p < 0.001
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50 % compared to WT tau (Fig. 2b, c; p < 0.001). There
were no significant differences between the amounts of
any of the other PXXP tau mutants tested (P176A,
P182A, P200A, P206A, or P233A), compared to WT tau
bound to fyn-SH3 (Fig. 2b, c). These results indicate that
the PXXP motif at P216-P219 of tau is important for
maintaining interactions between tau and fyn-SH3. Fur-
thermore, our findings show that disruption of a proline
residue closely apposed to the N-terminus of the sixth
PXXP motif also increases the interaction of tau with
fyn-SH3.
In agreement with previous studies reported by our
group and others [10, 11], binding of tau to fyn-SH3
was unaffected by substitution of P233 with alanine in
the seventh PXXP motif in tau (Fig. 2b, c). Despite re-
ports that removal of the PXXP motif at 233–236 of
tau inhibits its binding to fyn-SH3 [5], our data sup-
ports the idea that PXXP motifs N-terminal to P233 in
tau are more important for tau-fyn binding. However,
it should be noted that whilst both the individual
P216A and P219A tau mutations reduced tau binding
to fyn-SH3 by approximately 35 %, neither mutation
completely abolished the interaction of tau with fyn-
SH3. Thus it is likely that there are other regions of tau, in
addition to the individual proline residues located inside
the PXXP motifs, which are important for tau binding
to fyn-SH3.
Tau phosphorylation in Alzheimer’s disease brain is
unchanged at sites surrounding critical PXXP motifs
We and others have shown previously that tau phos-
phorylation can reduce its binding to fyn-SH3 [6, 7, 16].
The PXXP motif at residues 216–219 resides within a
region of tau that is enriched in serine/threonine phos-
phorylation sites [17]. Thus abnormal phosphorylation
of tau in AD could result in altered interactions between
tau and fyn-SH3. To determine the relationship between
tau phosphorylation and fyn, post-mortem human brain
tissue from controls (unaffected individuals and Braak
stages I–II) and from individuals with moderate to late
stage AD (Braak stages IV–VI) at autopsy was analysed
by western blot [18]. Probing with an antibody against
tau showed that, following standardisation to neuron-
specific enolase (NSE), the total amount of tau is highly
variable in post-mortem human brain, particularly in
AD (Fig. 3a). NSE standardisation allows for variable
neuronal loss due to differing degrees of neurodegenera-
tion in the human brain samples. The total amount of
tau present in AD brain at Braak IV–VI stages was
Fig. 3 Total tau is increased in AD brain whilst the amount of fyn is unchanged. a Western blots of control and Alzheimer’s disease (AD) post-mortem
human brain tissue probed with antibodies to total tau (upper panel) and neuron-specific enolase (NSE, lower panel). The amount of tau was
quantified relative to NSE in each sample (right). b Western blots of control and AD brain tissue probed with antibody against fyn (upper
panel). The amount of fyn was quantified relative to NSE in each sample (right). Molecular weight markers (kDa) are shown on the left. Values
represent mean ± SEM, n = 11–15 per group. Mann-Whitney non-parametric test, **p < 0.01, NS = not significant
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significantly increased compared to control brain (Fig. 3a;
p < 0.01), in agreement with previous reports [19, 20].
Probing the blots with an antibody against fyn showed
that after standardising to NSE, fyn was more consistent
within both control and AD brain, and that the total
amount of fyn was not significantly different between
control and AD brain (Fig. 3b).
Next, we analysed the human post-mortem brain tis-
sue for tau phosphorylation, particularly at serine/
threonine residues lying in close proximity to the
proline-rich region, and also towards the C-terminus of
tau. Tau phosphorylation was standardised to total tau,
to take into account the wide variation in the amount
of tau present in each brain sample. Tau-1, an antibody
which recognises tau when it is dephosphorylated at
S199/S202, revealed prominent bands corresponding to
normally phosphorylated tau in all samples tested
(Fig. 4a). Quantification of Tau-1 showed a 40 % de-
crease in Tau-1 immunoreactivity in AD compared to
control brain, indicating increased phosphorylation of
S199/S202 tau in AD, as expected [21] (Fig. 4a; p <
0.01). Tau immunoreactivity to CP13 antibody (tau
phosphorylated at S202) was barely detectable in con-
trols but immunoreactive bands at ~65–70 kDa were
recognised by this antibody in AD brain (Fig. 4b), as
shown previously [22]. The Odyssey imaging system
has a dynamic range of several orders of magnitude
and is capable of detecting immunoreactive bands that
may not be visible by eye, as demonstrated by the pres-
ence of CP13-immunoreactive bands in control brain
tissue in high-intensity scans (Additional file 1: Figure
S1a). Quantification of these CP13-immunoreactive tau
species relative to total tau revealed that phosphoryl-
ation at S202 of tau is significantly increased in AD
brain compared to controls (Fig. 4b; p < 0.01). Quantifi-
cation of blots probed for phosphorylation of tau at
S214, located within the fifth PXXP motif, showed that
this site on tau is phosphorylated similarly in both AD
and control brain, although the degree of phosphoryl-
ation showed a larger degree of variation in control
brain (Fig. 4c). Similarly to CP13, the pS262 tau anti-
body detected 65–70 kDa species in AD brain but not
in controls and these tau species were also found to be
significantly increased in AD, as previously shown [23]
(Fig. 4d; p < 0.01). The PHF-1 antibody (tau phosphory-
lated at S396/S404) showed barely any immunoreactiv-
ity in control brain and a significant increase in AD
brains compared to controls (Fig. 4e; p < 0.05), although
weak PHF-1 immunoreactivity can be observed in con-
trol brain tissue in high intensity blots (Additional file
1: Figure S1b). Taken together, these data show that con-
sistent with previous reports, increased phosphorylation at
tau epitopes corresponding to S199, S202, S262, and
S396/S404 are a feature of AD brain [20, 24–29].
Fyn is not correlated with tau phosphorylation in
Alzheimer’s disease brain
To determine whether there is a correlation between the
amount of fyn protein in AD and tau phosphorylation at
the epitopes investigated in this study, we performed a
non-parametric Spearman, or parametric Pearson correl-
ation analysis, depending on the normality of the data
distribution. Correlation between tau and fyn was first
examined in the combined cohort of control and AD pa-
tients, to investigate whether there was any association
irrespective of neuropathological status. We found no
significant correlation between the amount of fyn and ei-
ther total tau, or tau phosphorylated at S199/S202, S202,
S214, S262, or S396/S404 in the combined samples (data
not shown).
We next determined whether there was a correlation
between fyn and tau in the separate control and AD co-
horts that may be due to their differential neuropatho-
logical AD status (Fig. 5). A summary of the correlation
coefficients and significance levels obtained for correl-
ation between fyn and tau in control and AD brain is
shown in Table 3. This analysis revealed the interesting
findings that the amount of fyn present in control hu-
man brain correlated positively with the amount of tau
phosphorylated at S202 (CP13), S262, and S396/404
(PHF-1), but not at S214 (Table 3). In contrast there was
no correlation between fyn and phosphorylated tau in
AD brain, suggesting a potential disruption in the fyn-
tau relationship in AD. Our data support the hypothesis
that there may be an association between tau and fyn
under physiological conditions, but that pathological ac-
tivation of fyn or other disease-associated alterations in
fyn in AD may directly or indirectly impact regulation of
tau phosphorylation, or vice versa.
Discussion
The interaction between tau and fyn has recently
been proposed as a possible therapeutic target for
AD [11, 30–32]. Aberrant mislocalisation, or post-
translational modification, of tau and/or fyn under
pathological conditions could lead to altered binding
between these two proteins [33]. A growing body of evi-
dence supports the hypothesis that tau-fyn interactions
play a role in regulating synaptic function [1, 8, 34]. Al-
tered binding between tau and fyn could lead to unwanted
downstream consequences in AD, triggering further
cascades that lead to synaptotoxicity. In particular, tau
and fyn appear to work in concert to promote NMDA
receptor stability [1, 34]. Furthermore, inhibiting fyn
kinase activity reduces tau aggregation in a transgenic
mouse model of AD, suggesting that tau-fyn interaction
could exacerbate tau pathology in AD [30, 35]. There-
fore, we sought to identify the physiologically important
binding site between tau and fyn, and to determine
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whether disease-related phosphorylation of tau was re-
lated to levels of fyn in pathogenic conditions.
In this study, we substituted individual proline resi-
dues with alanine in each of the seven PXXP motifs in
tau to determine the effect on its ability to bind to the
SH3 domain of fyn. We found that substitution of either
P216 or P219 in tau reduces tau binding, whereas the
P213A mutation increases the association of tau with
fyn-SH3. This indicates that fyn-SH3 binds to the sixth
PXXP motif of tau (residues 216–219), and that the fifth
PXXP motif of tau at 213–216 also plays an important
role in regulating tau-fyn-SH3 interaction.
We have demonstrated previously that replacing P216,
but not P233, with alanine reduces tau binding to fyn-
SH3 in CHO cells [10], and this finding has since been
confirmed in a more recent study using bioluminescence
resonance energy transfer in cells [11]. In contrast, earl-
ier in vitro studies, using truncated tau constructs, have
suggested that the seventh PXXP motif at residues
233–236, rather than the sixth motif (216–219) is more
important for tau-fyn binding [1, 5]. The reason for this
discrepancy is not known, but one possible explanation
could be differential binding and conformation of full-
length, intact human tau that was used in this study
and others that identified the sixth motif (P216–P219)
[10, 11]. In comparison, truncated tau was used in
other studies that identified the seventh PXXP motif
(P233–P236) [1, 5].
PXXP-containing ligands are categorised as either
class I or II, with consensus sequences of RPL[PPXP]
or XXX[PXXP]XR respectively, depending on whether
the flanking by positively charged residues are located
N or C terminal to the PXXP motif [36]. Class I and II
ligands differ in the orientation in which they bind to
SH3 domains and, whereas SH3 domains can exhibit a
preference for either class of ligand, fyn-SH3 binds to
both classes [36–38]. In contrast to previous reports in
which the tau PXXP motif at 233–236 appeared to be
important for binding to fyn-SH3 [1, 5], we show here
that tau residues 213–219 are responsible for this inter-
action, with the sixth motif (P216–P219) enabling binding.
Furthermore, we have identified a potential regulatory role
for P213 in the fifth PXXP motif in tau since mutation of
this residue results in increased binding to fyn. The amino
acid sequences flanking the fifth, sixth and seventh
PXXP motifs in tau are 208-SRSRT[PSLP]TPPT-220,
211-RTPSL[PTPP]TREP-223, and 228-VVRTP[PKSP]S
SAK-240, respectively. Therefore, the fifth (P213–P216)
and seventh (P233–P236) PXXP motifs show some
similarity with class I ligands, whereas the sixth motif
(P216–P219) meets the consensus requirements of a
class II ligand. Although fyn-SH3 can bind to both
class I and II ligands, interaction with tau could be
dependent on its conformation, such that fyn-SH3
might favour binding to the sixth PXXP motif as a class
II ligand. However, this has not yet been examined and
the functional implications of SH3 domain binding to
class I or II PXXP ligands are not well defined.
The sixth tau PXXP motif (P216–P219) appears to be
the preferred binding domain for fyn-SH3, although
disruption to this region of tau could enable fyn to bind
to alternative PXXP motifs in tau. The fact that none of
the individual proline to alanine substitutions in tau ex-
amined here completely abolished fyn-SH3 binding,
suggests that fyn-SH3 has the capacity to bind to differ-
ent PXXP motifs under different physiological and
pathological conditions. Further support for this hy-
pothesis comes from a study by Ittner et al. [1] who
demonstrated that a truncated tau construct (residues
1–196), containing the N-terminus and the first two
PXXP motifs, did not bind fyn in transfected HEK293T
cells, whereas another truncated N-terminal tau con-
struct (1–221), that included the sixth PXXP motif, ex-
hibited reduced binding to fyn compared to full-length
tau. Thus, exclusion of the seventh PXXP motif (resi-
dues P233–P236) and the remaining C-terminal resi-
dues was insufficient to completely abolish tau-fyn-SH3
binding [1], suggesting a role for other regions of tau in
mediating binding with fyn-SH3.
Interestingly, we found that the P213A tau mutation
resulted in an increased amount of tau bound to fyn-
SH3. One possibility is that the alanine substitution at
this residue alters the conformation of tau to make it
more favourable for binding to fyn-SH3, providing that
the sixth PXXP motif is also present. It has been shown
that specific residues outside the core PXXP ligand can
contribute to the binding between PXXP motifs and
SH3 domains [39], which could explain the increased
binding affinity between P213A mutant tau and fyn-
SH3. For example, a serine residue located close to the
PXXP motif is important for binding to the SH3 do-
main of the adaptor protein, Nck (non-catalytic region
of tyrosine kinase adaptor protein 1) [40]. Residues lo-
cated C-terminal to PXXP motifs can also modulate
(See figure on previous page.)
Fig. 4 Altered tau and fyn expression at late stages of AD. Western blots of control and Alzheimer’s disease (AD) post-mortem human brain tissue
probed with antibodies recognising (a) tau dephosphosphorylated at S199/S202 (Tau-1), b tau phosphorylated at S202 (CP13), c tau phosphorylated at
S214, d tau phosphorylated at S262, and (e) tau phosphorylated at S306/S404 (PHF-1). Quantification of each epitope relative to total tau is shown on
the right. Molecular weight markers (kDa) are shown on the left. Values represent mean ± SEM, n = 11–15 per group. Mann-Whitney
non-parametric test, *p < 0.05, **p < 0.01, NS = not significant
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binding to fyn-SH3, although residues N-terminal to
PXXP have not yet been examined [41]. Thus, if fyn-
SH3 binds to tau at residues 216–219, the proline to
alanine substitution at 213 of tau could result in increased
binding affinity with fyn-SH3. Another possibility is that
the P213A mutation may alter tau phosphorylation
around this PXXP motif, which could enhance tau-fyn
binding at the SH3 domain.
In a related study, we showed previously that the
phosphorylation status of residues S199/S202 in tau in-
fluences its binding to fyn-SH3 [6], but the effects of
tau phosphorylation at other residues on tau-fyn bind-
ing have not been determined. The proline-rich region
of tau, which contains the PXXP motifs, also includes a
high density of serine/threonine residues [17]. There-
fore, it is likely that phosphorylation, or other post-
translational modifications, of residues surrounding the
sixth PXXP motif of tau, could influence its binding to
fyn-SH3. Substitution of 18 serine and threonine resi-
dues in the N-terminal half of tau to glutamate, to
mimic a state of permanent phosphorylation, inhibits
its binding to fyn-SH3 [7]. These mutations include 11
residues which are located within the proline-rich region
of tau. Binding of tau to fyn-SH3 was also abolished using
Tau-Glu10, a construct that mimics permanent phosphor-
ylation at ten serine/threonine sites, including five in the
proline-rich region [7]. Additionally, fyn-SH3 is unable to
bind to highly phosphorylated tau extracted from AD
brain [7]. Therefore, it appears that serine/threonine
phosphorylation of tau influences its interaction with
fyn-SH3, and much of this phosphorylation occurs
around the PXXP motifs (P213-P219) identified here as
being important for binding between tau and fyn-SH3.
However, the relationship of fyn with total tau or tau
phosphorylation has not been previously investigated in
AD. In agreement with previous reports, and despite the
wide variation between individuals with AD, we detected
increased tau in AD brain [19, 20].
We found no significant correlation between the
amount of fyn present and the degree of tau phosphoryl-
ation in AD brain tissue, suggesting that modification of
tau phosphorylation, at least at the serine/threonine resi-
dues examined in this study, does not result or lead to
increased fyn in AD. Interestingly, in control brain tis-
sue, although the amount of fyn did not correlate with
tau phosphorylation at residues S199 or S214, there was
a significant positive correlation between fyn and tau
phosphorylated at S202, S262, and S396/404. The ab-
sence of this correlation in AD brain suggests that, at
least during moderate to late stages of AD (Braak IV–
VI), underlying pathogenic mechanisms may disrupt the
association between fyn and tau phosphorylated at S202,
S262, and S396/404. Notably, inhibition of casein kinase
1 delta, which phosphorylates tau [42], in primary cor-
tical neurons, results in dephosphorylation of tau at
multiple sites, including S202, and increases the associ-
ation of tau with fyn-SH3 [6]. In contrast, increasing tau
phosphorylation using the protein phosphatase inhibitor
okadaic acid decreases tau binding to fyn-SH3 [6]. An
aspartate phosphomimic of tau at S202 has altered affin-
ity for fyn in vitro, dependent on the presence of the
microtubule-binding repeats of tau [16]. Phosphorylation
at S262 of tau has been shown to result in detachment
of tau from microtubules and decreased microtubule
stability, as well as inhibition of tau aggregation [42, 43].
Our results could indicate therefore that disassociation
of tau from microtubules might affect fyn expression,
or that the presence of fyn could influence tau phos-
phorylation at these residues when tau is not bound to
microtubules. It is plausible that tau phosphorylated at
S202 and S262 can bind to fyn or influence fyn expres-
sion or function under basal conditions, but at late
stages of AD, tau becomes increasingly phosphorylated
at other residues which could alter the its subcellular
localisation or conformation and cause the loss of tau-fyn
binding. The progressive accumulation of tau into aggre-
gates in AD could also result in the loss of the association
with fyn. Additionally, it was recently shown that tau
(See figure on previous page.)
Fig. 5 Correlation analysis of disease-related changes in tau and fyn in Alzheimer’s disease brain. a Total tau, expressed relative to neuron-specific
enolase (NSE), and (b-f) tau phospho-epitopes Tau-1; CP13; pS214; pS262; and PHF-1, expressed relative to total tau were compared to the
amount of fyn relative to NSE in post-mortem control and Alzheimer’s disease (AD) human brain. Pearson’s or Spearman’s rank correlation
analysis showed significant correlation of fyn with CP13, pS262, and PHF-1 in control brain, but not in AD brain (details in Table 3), as
indicated by a line of best fit
Table 3 Correlation analysis between tau and fyn in control
and Alzheimer’s disease brain
Control AD
Fyn vs r r
Total tau −0.468 0.156
Tau-1 0.258 −0.120
CP13 0.673* 0.041
Tau pS214 0.570 −0.078
Tau pS262 0.777** −0.121
PHF-1 0.837** 0.002
Pearson’s or Spearman’s rank correlation coefficients (r) corresponding to
associations between fyn, and tau (total or phosphorylated). Correlation
analyses were carried out on brains from either controls or Alzheimer’s disease
(AD); *p < 0.05, **p < 0.01
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phosphorylation at S396 is induced following NMDA-
receptor mediated long-term depression [4]. Indeed,
NMDA receptor activation increased the association of
tau phosphorylated at S396/404 with fyn [4]. Taken to-
gether, the significant correlation of phosphorylated S396/
404 tau with fyn in control brain tissue supports the idea
that NMDA receptor activation enhances tau-fyn associ-
ation. Conversely, the lack of significant correlation
between tau phosphorylated at this epitope and fyn in AD
brain suggests that pathogenic disease-related mecha-
nisms could interfere with the relationship between phos-
phorylated tau and fyn. Additional studies involving
analysis of fyn kinase activity would likely provide more
insight as to the role of fyn in regulating downstream
effects of tau phosphorylation and vice versa. Hence,
additional investigation is required to fully understand the
relationship between fyn and tau phosphorylation, in par-
ticular at residues S202, S262, and S396/404 in AD brain.
Conclusions
In this study, identification of the binding site between tau
and fyn-SH3 may facilitate the development of compounds
that can inhibit tau-fyn interactions, which presents an
alternative therapeutic strategy for AD. We also provide
evidence that a physiological correlation between phos-
phorylated tau at S202, S262, and S396/404 and fyn is not
present in AD brain, suggesting that progression of disease
pathogenesis can influence the relationship between tau
and fyn. Further investigation as to the relationship
between fyn kinase activity and tau phosphorylation will
be important in developing novel therapeutics for AD.
Additional file
Additional file 1: Figure S1. High intensity scans of western blots of
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(CP13) and (b) S396/S404 (PHF-1) in control brain tissue, whereas the signal
in AD brain is overexposed when shown at this intensity. The molecular
weight marker (50 kDa) is shown on the left. (PDF 2638 kb)
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